Epilepsy<unk>  is approved in the United States, and United Kingdom for adjunctive treatment of partial seizures in adults and Japan for both adjunctive and monotherapy for partial seizures (simple, complex, secondarily generalized), generalized (tonic, tonic-clonic (grand mal), and atypical absence) and combined seizures. In Australia it is marketed as both an adjunctive therapy and monotherapy for partial seizures only. Parkinson's disease It has been approved for the treatment of the motor symptoms of Parkinson's disease (PD), as an adjunct to levodopa, in a few countries such as Japan. In Japan,<unk>  has been used as an adjunct to levodopa treatment since 2009. In addition, there is clinical evidence that<unk>  in combination with levodopa control of motor symptoms of PD but evidence for the treatment of the non motor symptoms of PD lacking. Tardive dyskinesia In an open-label trial<unk>  attenuated the symptoms of tardive dyskinesia. Obesity It has also been studied for obesity with significant positive effects on body weight loss and there are three ongoing clinical trials for this indication. It was to be sold, when combined with bupropion, under the brand name Empatic, until its development was discontinued. Migraine<unk>  has been studied for and used as a migraine preventative medication, when topiramate is either ineffective or cannot be continued due to side effects. Bipolar depression It has also been used off-label by psychiatrists as a mood stabilizer to treat bipolar depression.
Zonisamide
Galantamine
Mesuximide
Ethosuximide
Phenytoin
Propazepine
Levetiracetam
Carbamazepine